校正:两种小分子抑制剂,用于Toxoplasma gondii的体外增殖
Qian-Qian Hua1, Xue-Jing Lin2, Shi-Peng Xiang2
1Department of Clinical Laboratory, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Frontiers in cellular and infection microbiology
|December 18, 2023
概括
这项研究纠正了之前的文章DOI. 修正后的DOI是10.3389/fcimb.2023.1145824,确保正确的引用和访问研究结果.
科学领域:
- 纠正科学文献参考文献.
- 确保科学出版物中准确的引用实践.
背景情况:
- 以前的出版物有一个错误的文章DOI.
- 准确的DOI对于科学文献的可发现性和获取性至关重要.
研究的目的:
- 为以前发表的文章提供正确的DOI.
- 为了促进研究的准确引用和检索.
主要方法:
- 错误的DOI的识别.错误的DOI的识别.
- 验证和确认正确的DOI.
主要成果:
- 该产品的正确标识是10.3389/fcimb.2023.1145824. 正确的标识是10.3389/fcimb.2023.1145824.
- 这种纠正确保了科学记录的完整性.
结论:
- 修正后的DOI现在可用于所有未来的引用.
- 这确保研究人员能够准确地访问和引用相关研究.
更多相关视频
相关概念视频
Toxoplasmosis
Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


